Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and…
- Trial name
- NCT02552849
- Testing
- No intervention
- Where
- 26 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Interstitial Lung Disease, IPF
ILAs in CT Lung Cancer Screening Population
Interstitial Lung Abnormalities (ILA) have been previously defined as nondependent changes affecting more than 5% of any lung zone on computed tomography (CT) scans of the lung.
- Trial name
- NCT04503044
- Testing
- Retrospective observational study
- Where
- United States
- Volunteers
- 1,703 people
- Sponsor
- Lahey Clinic
Lung Disease Chronic, Lung Diseases, Interstitial
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases
The investigators aim to study the effect of SOT in subjects with chronic lung disease in submaximal exercise.
- Conditions
- Lung Disease Chronic, Lung Diseases, Interstitial, Lung Diseases, Obstructive
- Trial name
- NCT06385301
- Testing
- 6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Rheumatoid Arthritis Interstitial Lung Disease
Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
- Trial name
- NCT02808871
- Testing
- Pirfenidone
- Where
- 33 sites in United States, Australia and 2 more
- Volunteers
- 123 people
- Sponsor
- Brigham and Women's Hospital
Lung Diseases, Interstitial, Systemic Sclerosis
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
- Conditions
- Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
- Trial name
- NCT02370693
- Testing
- Bortezomib, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Idiopathic Pulmonary Fibrosis, Depression
Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the effects of adding a palliative care intervention for patients with idiopathic pulmonary fibrosis (IPF) to current standard of care.
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder
- Trial name
- NCT03981406
- Testing
- Palliative Care, Standard of Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
Lung Disease
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
The investigators hypothesise that H2H will result in improved symptom control and quality of life and may be more cost-effective than standard best practice.
- Trial name
- H2H-ILD (NCT01450644)
- Testing
- The Hospital2Home Service
- Where
- 2 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Recurrent Ependymoma, Recurrent Ewing Sarcoma
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or…
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis
- Trial name
- NCT04195555
- Testing
- Ivosidenib
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy
Study of Default Options in Advance Directives
Default options represent the events or conditions that are set into place if no alternatives are actively chosen. The setting of default options has well-established effects on a broad range of human decisions, but its influence…
- Conditions
- COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy
- Trial name
- NCT01817686
- Testing
- Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Idiopathic Pulmonary Fibrosis (IPF)
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07464912
- Testing
- TDI01
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Interstitial Lung Disease
Interstitial Lung Disease Questionnaire
1. To evaluate the health status of patients with Interstitial Lung Disease (ILD), and how this varies between subgroups of ILD. 2.
- Trial name
- NCT01711151
- Where
- United Kingdom
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.
- Trial name
- BIANCA-SC (NCT01598857)
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Transbronchial Cryobiopsy, Anesthesia
The Impacts of the Different Anesthesia Methods on Patients of Transbronchial Cryobiopsy
to evaluate the difference between the tracheal intubation (TI) and rigid bronchoscopy (RB) under general anesthesia on patients with transbronchial cryobiopsy.
- Conditions
- Transbronchial Cryobiopsy, Anesthesia, Tracheal Intubation, Rigid Bronchoscopy
- Trial name
- NCT04099069
- Testing
- anesthesia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Carcinoma, Non-small-cell Lung
Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer
The purpose of this study is to evaluate the interest of breath holding for the prevention of radiation pneumonitis following conformal radiation therapy.
- Trial name
- NCT00349102
- Testing
- Free breathing, Breath holding
- Where
- 7 sites in France
- Volunteers
- 242 people
- Sponsor
- Centre Leon Berard
Radiation Pneumonitis
Study on the Biological Prediction Models of Radiation Pneumonitis
Radiation pneumonitis is the most common complication and the major dose-limiting toxicity associated with radiotherapy, which can cause poor quality of life or life-threatening symptoms and might hinder the tumor-controlling…
- Trial name
- NCT02490319
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huazhong University of Science and Technology
Lung Diseases, Interstitial
Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study
The purpose of this study is to evaluate the diagnostic yield and safety of transbronchial lung biopsies (TBLB) with cryoprobe versus conventional forceps in patients with diffuse lung disease.
- Trial name
- NCT02464592
- Testing
- Transbronchial lung biopsy.
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Radiation Toxicity
Oligo-Fucoidan Decrease Lung Radiation Damage
Fucoidan is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans…
- Trial name
- FIRILI (NCT05616507)
- Testing
- fucoidan
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Interstitial Lung Disease, Obstructive Sleep Apnea
Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD
The purpose of this study is to evaluate whether biomarkers of lung epithelial and endothelial injury are associated with obstructive sleep apnea (OSA) and interstitial lung disease (ILD).
- Trial name
- NCT03901534
- Testing
- Continuous positive airway pressure (CPAP) therapy, Nox A1 Recorder
- Where
- 2 sites in United States
- Volunteers
- 2,021 people
- Sponsor
- Columbia University
Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease
Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD
The aim of this prospective observational trial is to evaluate the influence of Coping strategies on pulmonary rehabilitation outcomes like 6-minute walk distance and Quality of life.
- Trial name
- NCT04257630
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Idiopathic Pulmonary Fibrosis
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02477709
- Testing
- Gefapixant
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.